Keynote Address: Man, Mice, Microsomes, Metabolites, and Mathematics 40 Years after the Revolution

References

• Berg P. Acyl adenylates: An enzymatic mechanism of acetate activation. J. Biol. Chem. 1956; 222: 991–1013
   PubMed Web of Science ®Google Scholar
• Jencks W. P., Lipmann F. Studies on the initial step of fatty acid activation. J. Biol. Chem. 1957; 225: 207–233
   PubMed Web of Science ®Google Scholar
• Schachter D., Taggart J. V. Glycine N-acetylase: Purification and properties. J. Biol. Chem. 1954; 208: 263–275
   PubMed Web of Science ®Google Scholar
• Moldave K., Meister A. Enzymic acylation of glutamine by phenylacetic acid. Biochim. Biophys. Acta 1957; 24: 654–655
   PubMed Web of Science ®Google Scholar
• Moldave K., Meister A. Participation of phenylacetyladenyl-ate in the enzymic synthesis of phenylacetylglutamine. Biochim. Biophys. Acta 1957; 25: 434–435
   PubMed Web of Science ®Google Scholar
• Dutton G. J., Storey I. D. E. Glucuronide synthesis in liver homogenates. Biochem. J 1951; 48(xxix)
   PubMedGoogle Scholar
• Dutton G. J., Storey I. D. E. Uridine compounds in glucuronic acid metabolism. 1. The formation of glucuronides in liver suspensions. Biochem. J. 1954; 57: 275–283
   PubMed Web of Science ®Google Scholar
• Storey I. D. E., Dutton G. J. Uridine compounds in glucuronic acid metabolism. 2. The isolation and structure of uridine-diphosphate-glucuronic acid. Biochem. J. 1955; 59: 279–287
   PubMed Web of Science ®Google Scholar
• Dutton G. J. Uridine diphosphate glucuronic acid as a glucuronyl donor in the synthesis of “ester,” aliphatic and steroid glucuronides. Biochem. J. 1956; 64: 693–701
   PubMed Web of Science ®Google Scholar
• Strominger J. L., Maxwell E. S., Axelrod J., Kalcker H. M. Enzymatic formation of uridine diphosphoglucuronic acid. J. Biol. Chem. 1957; 224: 79–90
   PubMed Web of Science ®Google Scholar
• Axelrod J., Inscoe J. K., Tomkins G. M. Enzymatic synthesis of N-glucosyluronic acid conjugates. J. Biol. Chem. 1958; 232: 835–840
   PubMed Web of Science ®Google Scholar
• Cramer J. W., Miller J. A., Miller E. C. N-Hydroxylation: A new metabolic reaction observed in the rat with the carcinogen 2-acetylaminofluorene. J. Biol. Chem. 1960; 235: 885–888
   PubMed Web of Science ®Google Scholar
• Isselbacher K. J., Axelrod J. Enzymatic formation of corticosteroid glucuronides. J. Am. Chem. Soc 1955; 27: 1070–1071
   Google Scholar
• Strominger H. M., Maxwell E. S., Axelrod J., Kalckar H. M. Enzymatic formation of uridine diphosphoglucuronic acid. J. Biol. Chem. 1957; 224: 79–90
   PubMed Web of Science ®Google Scholar
• Robbins P. W., Lipmann F. Separation of the two enzymatic phases in active sulfate synthesis. J. Biol. Chem. 1958; 233: 681–685
   PubMed Web of Science ®Google Scholar
• Robbins P. W., Lipmann F. Enzymatic synthesis of adenos-ine-5′-phosphosulfate. J. Biol. Chem. 1958; 233: 686–690
   PubMed Web of Science ®Google Scholar
• Cantoni G. L. S-Adenosylmethionine: A new intermediate formed enzymatically from L-methionine and adenosinetriphosphate. J. Biol. Chem. 1953; 204: 403–416
   PubMed Web of Science ®Google Scholar
• Cantoni G. L., Durell J. Activation of methionine for transmethylation. II. The methionine-activating enzyme: Studies on the mechanism of reaction. J. Biol. Chem. 1953; 225: 1033–1048
   Google Scholar
• Axelrod J., Senoh S., Witkop B. O-Methylation of catecholamines. in vivo, J. Biol. Chem. 1958; 233: 607–701
   Google Scholar
• Axelrod J., Tomchick R. Enzymatic O-methylation of epinephrine and other catechols. J. Biol. Chem. 1958; 233: 702–705
   PubMed Web of Science ®Google Scholar
• Barnes M. M., James S. P., Wood P. B. The formation of mercapturic acids. 1. Formation of mercapturic acids and levels of glutathione in tissues. Biochem. J. 1959; 71: 680–690
   PubMed Web of Science ®Google Scholar
• Knight R. H., Young L. The urinary excretion of premer-capturic acids. Biochem. J 1957; 66: P55
   Web of Science ®Google Scholar
• Boyland E., Sims P., Solomon J. B. Metabolism of polycy-clic hydrocarbons. 11. The conversion of naphthalene into 2-hy-droxy-1-naphthyl sulfate. Biochem. J. 1957; 66: 38–40
   PubMed Web of Science ®Google Scholar
• Boyland E., Sims P. Metabolism of polycyclic hydrocarbons. 12. An acid-labile precursor of 1-naphthylmercapturic acid and naphthol: An A^-acetyl-5-(l:2-dihydrodihydroxynaphthyl) L-cysteine. Biochem. J. 1958; 68: 440–447
   PubMed Web of Science ®Google Scholar
• Mueller G. C., Miller J. A. The reductive cleavage of 4-dimethylaminoazobenzene by rat liver. Reactivation of carbon dioxide treated homogenates by riboflavin-adenine dinucleotide. J. Biol. Chem. 1950; 185: 145–154
   PubMed Web of Science ®Google Scholar
• Fouts J. R., Kamm J. J., Brodie B. B. Enzymatic reduction of prontosil and other azo dyes. J. Pharmacol. Exp. Ther. 1957; 120: 291–300
   PubMed Web of Science ®Google Scholar
• Fouts J. R., Brodie B. B. The enzymatic reaction of chloramphenicol, p-nitrobenzoic acid, and other aromatic nitro compounds in mammals. J. Pharmacol. Exp. Ther. 1957; 119: 197–207
   PubMed Web of Science ®Google Scholar
• Butler T. C. Reduction of carbon tetrachloride in vivo by tissues and tissue constituents. J. Pharmacol. Exp. Ther. 1961; 134: 311–319
   PubMed Web of Science ®Google Scholar
• Mueller G. C., Miller J. A. The metabolism of methylated aminoazo dyes. II. Oxidative demethylation of rat liver microsomes. J. Biol. Chem. 1953; 202: 579–587
   PubMed Web of Science ®Google Scholar
• Axelrod J. The enzymatic deamination of amphetamine (Benzedrine). J. Biol. Chem. 1955; 214: 753–763
   PubMedGoogle Scholar
• Brodie B. B., Axelrod J., Cooper J. R., Gaudette L., La Du B. N., Mitoma C., Udenfriend S. Detoxification of drugs and other foreign compounds by liver microsomes. Science 1955; 121: 603–604
   PubMed Web of Science ®Google Scholar
• La Du B. N., Gaudette L., Trousof N., Brodie B. B. Enzymatic dealkylation of aminopyrine (Pyramidon) and other alkyl-amines. J. Biol. Chem. 1955; 214: 741–752
   PubMedGoogle Scholar
• Axelrod J. The enzymic cleavage of aromatic ethers. Biochem. J. 1956; 63: 634–639
   PubMed Web of Science ®Google Scholar
• Cooper J. R., Brodie B. B. The enzymatic metabolism of hexobarbital (Evipal). J. Pharmacol. Exp. Ther. 1955; 114: 409–417
   PubMed Web of Science ®Google Scholar
• Mitoma C., Posner H. S., Reitz H. C., Udenfriend S. Enzymatic hydroxylation of aromatic compounds. Arch. Biochem. Biophys. 1956; 61: 431–441
   PubMed Web of Science ®Google Scholar
• Boyland E. Biological significance of metabolism of hydrocarbons. Symp. Biochem. Soc 1950; 5: 40–54
   Web of Science ®Google Scholar
• Booth J., Boyland E., Sato T., Sims P. Metabolism of poly-cyclic hydrocarbons. 17. The reaction of 1:2-dihydronaphthalene and l:2-epoxy 1,2,3,4-tetrahydronaphthalene with glutathione catalyzed by tissue preparations. Biochem. J. 1960; 77: 182–186
   PubMed Web of Science ®Google Scholar
• Holtzman J. L., Gillette J. R., Milne G. W. A. The incorporation of 18O into naphthalene in the enzymatic formation of 1,2-dihydronaphthalene-l,2-diol. J. Biol. Chem. 1967; 242: 4386–4387
   PubMed Web of Science ®Google Scholar
• Jerina D. M., Daly J. W., Witkop B., Zaltzman-Nirenberg P., Udenfriend S. The role of arene oxide-oxepin systems in the metabolism of aromatic substrates. 3. Formation of 1,2-naphthalene oxide from naphthalene by liver microsomes. J. Am. Chem. Soc 1968; 90: 6525–6527
   PubMed Web of Science ®Google Scholar
• Cooper J. R., Axelrod J., Brodie B. B. Inhibitory effects of P-diethylaminoethyl diphenylpropylacetate on a variety of drug metabolic pathways in vitro. J. Pharmacol. Exp. Ther 1954; 112: 55–63
   PubMed Web of Science ®Google Scholar
• Axelrod J., Reichental J., Brodie B. B. Mechanism of the potentiating action of β-diethylaminoethyl diphenylpropylacetate. J. Pharmacol. Exp. Ther. 1954; 112: 49–54
   PubMed Web of Science ®Google Scholar
• Fouts J. R., Brodie B. B. Inhibition of drug metabolic pathways by the potentiating agent 2,4-dichloro-6-phenylphenoxyethyl diethylamine. J. Pharmacol. Exp. Ther. 1955; 115: 68–73
   PubMed Web of Science ®Google Scholar
• Fouts J. R., Brodie B. B. On the mechanism of drug potentiation by iproniazid (2-isopropyl-l-isonicotinyl hydrazine). J. Pharmacol. Exp. Ther. 1956; 116: 480–485
   PubMed Web of Science ®Google Scholar
• Conney A. H., Miller E. C., Miller J. A. The metabolism of methylated aminoazo dyes. V. Evidence for induction of enzyme synthesis in the rat by 3-methylcholanthrene. Cancer Res. 1956; 16: 450–459
   PubMed Web of Science ®Google Scholar
• Remmer H. Die Beschleunigung des Evipanabbaues unter der Wirkung von Barbituraten,. Naturwissenschaften 1958; 45: 189
   Web of Science ®Google Scholar
• Conney A. H., Burns J. J. Stimulatory effects of foreign compounds on ascorbic acid biosynthesis and on drug-metabolizing enzymes. Nature, London 1959; 184: 363–364
   PubMed Web of Science ®Google Scholar
• Conney A. H., Gillette J. R., Inscoe J. K., Trams E. B., Posner H. S. Induced synthesis of liver microsomal enzymes which metabolize foreign compounds. Science 1959; 130: 1478–1479
   PubMed Web of Science ®Google Scholar
• Conney A. H. Pharmacological implications of microsomal enzyme induction. Pharmacol. Rev. 1967; 19: 317–366
   PubMed Web of Science ®Google Scholar
• Klingenberg M. Pigments in rat liver microsomes. Arch. Biochem. Biophys. 1958; 75: 376–386
   PubMed Web of Science ®Google Scholar
• Garfinkel D. Studies on pig liver microsomes. I. Enzymic and pigment composition of different microsomal fractions. Arch. Biochem. Biophys. 1958; 77: 493–509
   PubMed Web of Science ®Google Scholar
• Horecker B. L. Triphosphopyridine nucleotide-cytochrome c reductase in liver. J. Biol. Chem. 1950; 183: 593–605
   Web of Science ®Google Scholar
• Gillette J. R., Brodie B. B., La Du B. M. The oxidation of drugs by liver microsomes: On the role of TPNH and oxygen. J. Pharmacol. Exp. Ther. 1957; 119: 532–540
   PubMed Web of Science ®Google Scholar
• Ryan K. J., Engel L. L. Hydroxylation of steroids at carbon 21. J. Biol. Chem. 1957; 225: 103–114
   PubMed Web of Science ®Google Scholar
• Omura T., Sato R. The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J. Biol. Chem. 1964; 239: 2370–2378
   PubMed Web of Science ®Google Scholar
• Omura T., Sato R. The carbon monoxide-binding pigment of liver microsomes. II. Solubilization, purification, and properties. J. Biol. Chem. 1964; 239: 2378–2385
   Web of Science ®Google Scholar
• Estabrook R. W., Cooper D. Y., Rosenthal O. The light reversible carbon monoxide inhibition of the steroid C21-hydroxylase system in the adrenal cortex. Biochem. Z. 1963; 338: 741–755
   PubMedGoogle Scholar
• Cooper D. V., Levin S., Narasimhulu S., Rosenthal O., Estabrook R. W. Photochemical action spectrum of the terminal oxidase of mixed function oxidase systems. Science 1965; 147: 400–402
   PubMed Web of Science ®Google Scholar
• Omura T., Sato R., Cooper D. Y., Rosenthal O., Estabrook R. W. Function of cytochrome P-450 of microsomes. Fed. Proc 1965; 24: 1181–1189
   PubMedGoogle Scholar
• Lu A. Y. H., Coon M. J. Role of hemoprotein P-450 in fatty acid omega-hydroxylation in a soluble enzyme system from liver microsomes. J. Biol. Chem. 1968; 243: 1331–1332
   PubMed Web of Science ®Google Scholar
• Miller E. C. Studies on the formation of protein-bound derivatives of 3,4-benzpyrene in the epidermal fraction of mouse skin. Cancer Res. 1951; 11: 100–108
   PubMed Web of Science ®Google Scholar
• Miller E. C., Miller J. A. In vivo combination between carcinogens and tissue constituents and their possible role in carcinogenesis. Cancer Res. 1952; 12: 547–556
   PubMed Web of Science ®Google Scholar
• Wiest W. G., Heidelberger C. The interaction of carcinogenic hydrocarbons with tissue constituents. II. 1,2,5,6-dibenzathracene-9,10-C14 in skin. Cancer Res. 1953; 13: 250–254
   PubMed Web of Science ®Google Scholar
• Riegel I. L., Mueller G. C. Formation of a protein-bound metabolite of estradiol-16-C14 by rat liver homogenates. J. Biol. Chem. 1954; 210: 249–257
   PubMed Web of Science ®Google Scholar
• Gelboin H. V., Miller J. A., Miller E. C. Studies on hepatic protein-bound dye formation in rats given single large doses of 3′ -rnethyl-4-dimethylaminoazobenzene. Cancer Res. 1958; 18: 608–617
   PubMed Web of Science ®Google Scholar
• Hecker E., Mueller G. C. Formation of tetralin-p-quinol and a protein-bound derivative from tetrahydro-2-naphthol-8-C14 by rat liver microsomes. J. Biol. Chem. 1958; 233: 991–996
   PubMed Web of Science ®Google Scholar
• Cramer J. W., Miller J. A., Miller E. C. The hydroxylation of the carcinogen 2-acetylaminofluorene by rat liver: Stimulation by treatment in vivo with 3-methylcholanthrene. J. Biol. Chem. 1960; 235: 250–256
   PubMed Web of Science ®Google Scholar
• Hultin T. Reactions of C14-labeled carcinogenic azo dyes with rat liver proteins. Exp. Cell Res. 1957; 13: 47–59
   PubMed Web of Science ®Google Scholar
• Hultin T. Reactions of 2-aminofluorene and related aromatic amines with liver proteins in vitro, Exp. Cell Res 1959; 18: 112–125
   Web of Science ®Google Scholar
• Decken A. von der, Hultin T. The enzymatic composition of rat liver microsomes during liver regeneration. Exp. Cell Res. 1960; 19: 591–603
   PubMed Web of Science ®Google Scholar
• Gutman H. R., Peters J. H. Studies on the action of rat liver on 2-acetylaminofluorene. J. Biol. Chem. 1954; 211: 63–74
   PubMed Web of Science ®Google Scholar
• Peters J. H., Gutman H. R. Stimulation of hydroxylation and protein binding of the carcinogen 2-acetylaminofluorene in rat liver homogenates. Arch. Biochem. Biophys. 1956; 62: 234–236
   PubMed Web of Science ®Google Scholar
• Gutman H. R., Peters J. H., Burtle J. G. The metabolism in vitro of fluorene derivatives by rat liver: Hydroxylation and protein binding. J. Biol. Chem. 1956; 222: 373–386
   PubMed Web of Science ®Google Scholar
• Dutton G. J., Greig C. G. Observations on the distribution of glucuronide synthesis in tissues. Biochem. J 1957; 66: 52P
   Web of Science ®Google Scholar
• Robinson D., Williams R. T. Do cats form glucuronides?. Biochem. J 1958; 68: 23P
   Web of Science ®Google Scholar
• Marshall E. K., Jr., Cutting W. C., Emerson K., Jr. Acety-lation of p-aminobenzene sulfonamide in the animal organism. Science 1937; 85: 202–203
   PubMedGoogle Scholar
• Muenzen J. B., Cerecedo L. R., Sherwin C. P. Comparative metabolism of certain aromatic acids. VIII. Acetylation of amino compounds. J. Biol. Chem. 1926; 67: 469–476
   Google Scholar
• Bray H. G., Franklin T. J., James S. P. N-Acetylation of S-substituted cysteine in the rabbit, rat, and guinea pig. Biochem. J. 1959; 73: 465–473
   PubMed Web of Science ®Google Scholar
• Axelrod J. Studies on sympathomimetic amines. II. The biotransformation and physiological disposition of d-amphetamine d-p-hydroxyamphetamine and d-methamphetamine. J. Pharmacol. Exp. Ther. 1954; 110: 315–326
   PubMed Web of Science ®Google Scholar
• Quinn G. P., Axelrod J., Brodie B. B. Species, strain, and sex differences in the metabolism of hexobarbitone, amidopyrine, antipyrine, and aniline. Biochem. Pharmacol 1958; 1: 152–159
   Web of Science ®Google Scholar
• Brodie B. B. Of mice, microsomes and man. Pharmacologist 1964; 6: 12–26
   Google Scholar
• Shannon J. A. The study of antimalarials and antimalarial activity in the human malarias. Harvey Led. Ser 1945; 41: 43–89, 1946
   PubMed Web of Science ®Google Scholar
• Shannon J. A., Earle D. P., Brodie B. B., Taggart J. V., Berliner R. W. The pharmacological basis for the rational use of Atabrine in the treatment of malaria. J. Pharmacol. Exp. Ther. 1944; 81: 307–330
   Google Scholar
• Williams R. T. Detoxification Mechanisms 2nd ed. Wiley & Sons, New York 1959
   Google Scholar
• Gillette J. R., Dingell J. V., Sulser F., Kuntzman R., Brodie B. B. Isolation from rat brain of a metabolic product, desmethyl-imipramine, that mediates the antidepressant activity of imipramine (Tofranil). Experientia 1961; 17: 377–432
   Google Scholar
• Brodie B. B., Bickel M. H., Sulser F. Desmethylimipramine, a new type of antidepressant drug. Med. Exp. 1961; 5: 454–458
   PubMedGoogle Scholar
• Dingell J. V., Sulser F., Gillette J. R. Species differences in the metabolism of imipramine and desmethylimipramine (DMI). J. Pharmacol. Exp. Ther. 1964; 143: 14–22
   PubMed Web of Science ®Google Scholar
• Schumacher H., Smith R. L., Williams R. T. The metabolism of thalidomide: The spontaneous hydrolysis of thalidomide in solution. Br. J. Pharmacol 1965; 25: 324–337
   PubMed Web of Science ®Google Scholar
• Schumacher H., Blake D. A., Gurian J. M., Gillette J. R. A comparison of the teratogenic activity of thalidomide in rabbits and rats. J. Pharmacol. Exp. Ther. 1968; 160: 189–200
   PubMed Web of Science ®Google Scholar
• Schumacher H., Blake D. A., Gillette J. R. Disposition of thalidomide in rabbits and rats. J. Pharmacol. Exp. Ther. 1968; 160: 201–211
   PubMed Web of Science ®Google Scholar
• Gordon G. B., Spielberg S. P., Blake D. A., Balasubra-manian V. Thalidomide teratogenesis: Evidence for a toxic arene oxide metabolite. Proc. Natl. Acad. Sci. USA 1981; 78: 2545–2548
   PubMed Web of Science ®Google Scholar
• Brodie B. B., Reid W. D., Cho A. K., Sipes G., Krishna G., Gillette J. R. Possible mechanism of liver necrosis caused by aromatic organic compounds. Proc. Natl. Acad. Sci. USA 1971; 68: 160–164
   PubMed Web of Science ®Google Scholar
• Reid W. R., Christie B., Krishna G., Mitchell J. R., Moskowitz J., Brodie B. B. Bromobenzene metabolism and hepatic necrosis. Pharmacology 1971; 6: 41–55
   PubMed Web of Science ®Google Scholar
• Reid W. D., Christie B., Eichelbaum M., Krishna G. 3-Methylcholanthrene blocks hepatic necrosis influenced by administration of bromobenzene or carbon tetrachloride. Exp. Mol. Pathol. 1971; 15: 363–372
   Web of Science ®Google Scholar
• Zampaglione N., Jollow D. J., Mitchell J. R., Stripp B., Hamrick M., Gillette J. R. Role of detoxifying enzymes in bro-mobenzene-induced liver necrosis. J. Pharmacol. Exp. Ther. 1973; 187: 218–227
   PubMed Web of Science ®Google Scholar
• Reid W. D. Mechanism of renal necrosis influenced by bromobenzene or chlorobenzene. Exp. Mol. Pathol. 1973; 19: 197–214
   PubMed Web of Science ®Google Scholar
• Jollow D. J., Mitchell J. R., Zampaglione N., Gillette J. R. Bromobenzene-induced liver necrosis, protective role of glutathione and evidence for 3,4-bromobenzene oxide as the hepatotoxic metabolite. Pharmacology 1974; 11: 151–169
   PubMed Web of Science ®Google Scholar
• Monks T. J., Pohl L. R., Gillette J. R., Hong M., Highet R. J., Ferretti J. A., Hinson J. A. Stereoselective formation of bromobenzene glutathione conjugates. Chem.-Biol. Interact. 1982; 41: 203–216
   PubMed Web of Science ®Google Scholar
• Monks T. J., Hinson J. A., Gillette J. R. Bromobenzene and p-bromophenol toxicity and covalent binding. in vivo, Life Set 1982; 30: 841–848
   PubMed Web of Science ®Google Scholar
• Monks T. J., Lau S. S., Highet R. J. Formation of nontoxic reactive metabolites of p-bromophenol. Identification of a new glutathione conjugate. Drug Metab. Dispos. 1984; 12: 432–437
   PubMed Web of Science ®Google Scholar
• Lau S. S., Monks T. J., Greene K. E., Gillette J. R. The role of ortho-bromophenol in the nephrotoxicity of bromobenzene in rats. Toxicol. Appl. Pharmacol. 1984; 72: 539–549
   PubMed Web of Science ®Google Scholar
• Monks T. J., Lau S. S., Pohl L. R., Gillette J. R. The mechanism of formation of o-bromophenol from bromobenzene. Drug Metab. Dispos. 1984; 12: 193–198
   PubMed Web of Science ®Google Scholar
• Lau S. S., Monks T. J., Gillette J. R. Multiple reactive metabolites derived from bromobenzene. Drug Metab. Dispos. 1984; 12: 291–296
   PubMed Web of Science ®Google Scholar
• Monks T. J., Lau S. S. Activation and detoxification of bromobenzene in extrahepatic tissues. Life Sci. 1984; 35: 561–568
   PubMed Web of Science ®Google Scholar
• Lau S. S., Monks T. J., Gillette J. R. Identification of 2-bromohydroquinone as a metabolite of bromobenzene and o-bromophenol: Implications for bromobenzene-induced nephrotoxicity. J. Pharmacol. Exp. Ther. 1984; 230: 360–366
   PubMed Web of Science ®Google Scholar
• Mitchell J. R., Jollow D. J., Potter W. Z., Davis D C., Gillette J. R., Brodie B. B. Acetaminophen-induced hepatic necrosis. I. Role of drug metabolism. J. Pharmacol. Exp. Ther. 1973; 187: 185–194
   PubMed Web of Science ®Google Scholar
• Jollow D. J., Mitchell J. R., Potter W. Z., Davis D. C., Gillette J. R., Brodie B. B. Acetaminophen-induced hepatic necrosis. II. Role of covalent binding in vivo. J. Pharmacol. Exp. Ther 1973; 187: 195–202
   PubMed Web of Science ®Google Scholar
• Potter W. Z., Davis D. C., Mitchell J. R., Jollow D. J., Gillette J. R., Brodie B. B. Acetaminophen-induced hepatic necrosis. III. Cytochrome P-450-mediated covalent binding in vitro. J. Pharmacol. Exp. Ther 1973; 187: 203–210
   PubMed Web of Science ®Google Scholar
• Mitchell J. R., Jollow D. J., Potter W. Z., Gillette J. R., Brodie B. B. Acetaminophen-induced hepatic necrosis. IV. Protective role of glutathione. J. Pharmacol. Exp. Ther. 1973; 187: 211–217
   PubMed Web of Science ®Google Scholar
• Davis D. C., Potter W. Z., Jollow D. J., Mitchell J. R. Species differences in hepatic glutathione depletion, covalent binding and hepatic necrosis after acetaminophen. Life Sci. 1974; 14: 2099–2109
   PubMed Web of Science ®Google Scholar
• Potter W. Z., Thorgeirsson S. S., Jollow D. J., Mitchell J. R. Acetaminophen-induced hepatic necrosis. V. Correlation of hepatic necrosis, covalent binding and glutathione depletion in hamsters. Pharmacology 1974; 12: 129–143
   PubMed Web of Science ®Google Scholar
• Jollow D. J., Thorgeirsson S. S., Potter W. Z., Hashimoto M., Mitchell J. R. Acetaminophen-induced hepatic necrosis. VI. Metabolic disposition of toxic and nontoxic doses of acetaminophen. Pharmacology 1974; 12: 251–271
   PubMed Web of Science ®Google Scholar
• Mitchell J. R., Thorgeirsson S. S., Potter W. Z., Jollow D. J., Keiser H. Acetaminophen-induced hepatic injury: Protective role of glutathione in man and rationale for possible therapy. Clin. Pharmacol. Ther. 1974; 16: 676–684
   PubMed Web of Science ®Google Scholar
• McMurtry R. J., Snodgrass W. R., Mitchell J. R. Renal necrosis, glutathione depletion and covalent binding after acetaminophen. Toxicol. Appl. Pharmacol. 1978; 46: 87–100
   PubMed Web of Science ®Google Scholar
• Hinson J. A., Pohl L. R., Gillette J. R. W-Hydroxyace-taminophen: A microsomal metabolite of N-hydroxyphenacetin but apparently not of acetaminophen. Life Sci. 1979; 24: 2133–2138
   PubMed Web of Science ®Google Scholar
• Rollins D. E., Buckpitt A. R. Liver cytosol catalyzed conjugation of reduced glutathione with a reactive metabolite of acetaminophen. Toxicol. Appl. Pharmacol 1979; 47: 331–339
   PubMed Web of Science ®Google Scholar
• Hinson J. A., Pohl L. R., Monks T. J., Gillette J. R. Ac-etaminophen-induced hepatotoxicity. Life Sci. 1981; 29: 107–116
   PubMed Web of Science ®Google Scholar
• Gillette J. R., Nelson S. D., Mulder G. J., Jollow D. J., Mitchell J. R., Pohl L. R., Hinson J. A. Formation of chemically reactive metabolites of phenacetin and acetaminophen. Biological Reactive Intermediates—II, Part B, R. Snyder, D. V. Parke, J. J. Kocsis, D. J. Jollow, C. M. Witmer. Plenum. 1982; 931–950
   Google Scholar
• Hinson J. A., Mitchell J. R., Jollow D. J. Microsomal N-hydroxylation of p-chloroacetanilide. Mol. Pharmacol. 1975; 11: 462–469
   Web of Science ®Google Scholar
• Hinson J. A., Mitchell J. R., Jollow D. J. N-Hydroxylation of p-chloroacetanilide in hamsters. Biochem. Pharmacol. 1976; 25: 599–601
   PubMed Web of Science ®Google Scholar
• Hinson J. A., Mitchell J. R. Af-Hydroxylation of phenacetin by hamster liver microsomes. Drug Metab. Dispos. 1976; 4: 430–435
   PubMed Web of Science ®Google Scholar
• Mulder G. J., Hinson J. A., Gillette J. R. Generation of reactive metabolites of N-hydroxy-phenacetin by glucuronidation and sulfation. Biochem. Pharmacol 1977; 26: 189–196
   PubMed Web of Science ®Google Scholar
• Hinson J. A., Nelson S. D., Mitchell J. R. Studies on the microsomal formation of arylating metabolites of acetaminophen and phenacetin. Mol. Pharmacol 1977; 13: 625–633
   PubMed Web of Science ®Google Scholar
• Mulder G. J., Hinson J. A., Gillette J. R. Conversion of the N-O-glucuronide and N-O-sulfate conjugates of W-hydroxyphenacetin to reactive intermediates. Biochem. Pharmacol 1978; 26: 1641–1649
   Google Scholar
• Nelson S. D., Garland W. A., Mitchell J. R., Vaishnav Y., Statham C. N., Buckpitt A. R. Deuterium isotope effects on the metabolism and toxicity of phenacetin in hamsters. Drug Metab. Dispos. 1978; 6: 363–367
   PubMed Web of Science ®Google Scholar
• Hinson J. A., Andrews L. S., Mulder G. J., Gillette J. R. Decomposition mechanisms of N-O-glucuronide and N-0-sulfate conjugates of phenacetin and other arylamides. Conjugation Reactions in Drug Biotransformation, A. Aitio. North-Holland Biomedical Press, Elsevier. 1978; 455–465
   Google Scholar
• Hinson J. A., Nelson S. D., Nelson, Gillette J. R. Metabolism of [p18O]-phenacetin: The mechanism of activation of phenacetin to reactive metabolites in hamsters. Mol. Pharmacol. 1979; 15: 419–427
   PubMed Web of Science ®Google Scholar
• Nelson S. D., Vaishnav Y., Gillette J. R., Hinson J. A. The use of 2H and 180 to examine arylating and alkylating pathways of phenacetin metabolism. Stable Isotopes: Proceedings of the Third International Conference. Academic Press, 1979; 385–392
   Google Scholar
• Hinson J. A., Andrews L. S., Gillette J. R. Kinetic evidence for multiple chemically reactive intermediates in the breakdown of phenacetin N-O-glucuronide. Pharmacology 1979; 19: 237–248
   PubMed Web of Science ®Google Scholar
• Nelson S. D., Forte A. J., Vaishnav Y., Mitchell J. R., Gillette J. R., Hinson J. A. The formation of arylating and alkylating metabolites of phenacetin in hamsters and hamster liver microsomes. Mol. Pharmacol. 1981; 19: 140–145
   PubMed Web of Science ®Google Scholar
• Black M., Mitchell J. R., Zimmerman H. J., Ishak K. G., Epler G. R. Isoniazid-associated hepatitis in 114 patients. Gastroenterology 1975; 69: 289–302
   PubMed Web of Science ®Google Scholar
• Mitchell J. R., Long M. W., Thorgeirsson U. P., Jollow D. J. Acetylation rates and monthly liver function tests during one year of isoniazid preventive therapy. Chest 1975; 69: 181–190
   Google Scholar
• Mitchell J. R., Thorgeirsson U. P., Black M., Timbrell J. A., Snodgrass W. R., Potter W. Z., Jollow D. J., Keiser H. R. Increased incidence of isoniazid hepatitis in rapid acetylators: Possible relation to hydrazine metabolites. Clin. Pharmacol. Ther. 1975; 18: 70–79
   PubMed Web of Science ®Google Scholar
• Mitchell J. R., Zimmerman H. J., Ishak K. G., Thorgeirsson U. P., Timbrell J. A., Snodgrass W. R., Nelson S. D. Isoniazid liver injury: Clinical spectrum, pathology and probable pathogenesis. Ann. Intern. Med. 1976; 84: 181–192
   PubMed Web of Science ®Google Scholar
• Nelson S. D., Mitchell J. R., Timbrell J. A., Snodgrass W. R., Corcoran G. B. Isoniazid and iproniazid: Activation of metabolites to toxic intermediates in man and rat. Science 1976; 193: 901–903
   PubMed Web of Science ®Google Scholar
• Timbrell J. A., Mitchell J. R., Snodgrass R., Nelson S. D. Isoniazid hepatotoxicity: The relationship between covalent binding and metabolism in vivo. J. Pharmacol. Exp. Ther 1980; 213: 364–369
   PubMed Web of Science ®Google Scholar
• Nelson S. D., Mitchell J. R., Snodgrass W. R., Timbrell J. A. Hepatotoxicity and metabolism of iproniazid and iso-propylhydrazine. J. Pharmacol. Exp. Ther. 1978; 206: 574–585
   PubMed Web of Science ®Google Scholar
• Boyd M. R. Role of metabolic activation in the pathogenesis of chemically induced pulmonary disease: Mechanism of action of the lung-toxic furan, 4-ipomeanol. Environ. Health Perspect. 1976; 16: 127–138
   PubMed Web of Science ®Google Scholar
• Boyd M. Evidence for the Clara cell as a site of cytochrome P450-dependent mixed-function oxidase activity in lung. Nature 1977; 269: 713–715
   PubMed Web of Science ®Google Scholar
• Sasame H. A., Gillette J. R., Boyd M. R. Effects of anti-NADPH cytochrome c reductase and anti-cytochrome b5 antibodies on the hepatic and pulmonary microsomal metabolism and co-valent binding of the pulmonary toxin 4-ipomeanol. Biochem. Biophys. Res. Commun. 1978; 84: 389–395
   PubMed Web of Science ®Google Scholar
• Boyd M. R., Burka L. T., Wilson B. J., Sasame H. A. In vitro studies on the metabolic activation of the pulmonary toxin 4-ipomeanol by rat lung and liver microsomes. J. Pharmacol. Exp. Ther. 1978; 207: 677–686
   PubMed Web of Science ®Google Scholar
• Dutcher J. S., Boyd M. R. Species and strain differences in target organ alkylation and toxicity by 4-ipomeanol predictive value of covalent binding in studies of target organ toxicities by reactive metabolites. Biochem. Pharmacol. 1979; 28: 3367–3372
   PubMed Web of Science ®Google Scholar
• Boyd M. R., Sasame H. A., Franklin R. B. Comparison or ratios of covalent binding to total metabolism of the pulmonary toxin 4-ipomeanol in vitro in pulmonary and hepatic microsomes, and the effects of pretreatments with phenobarbital or 3-methyl-cholanthrene. Biochem. Biophys. Res. Commun. 1980; 93: 1167–1172
   PubMed Web of Science ®Google Scholar
• Mitchell J. R., Potter W. Z., Hinson J. A., Jollow D. J. Hepatic necrosis caused by furosemide, a furan-containing diuretic. Nature 1974; 251: 508–511
   PubMed Web of Science ®Google Scholar
• Thorgeirsson S. S., Sasame H. A., Mitchell J. R., Jollow D. J., Potter W. Z. Biochemical changes after hepatic injury from toxic doses of acetaminophen or furosemide. Pharmacology 1976; 14: 205–217
   PubMed Web of Science ®Google Scholar
• Mitchell J. R., Nelson W. L., Potter W. Z., Sasame H. A., Jollow D. J. Metabolic activation of furosemide to a chemically reactive hepatotoxic metabolite. J. Pharmacol. Exp. Ther. 1976; 199: 41–52
   PubMed Web of Science ®Google Scholar
• McMurtry R. J., Mitchell J. R. Renal and hepatic necrosis after metabolic activation of 2-substituted furans and thiophenes, including furosemide and cephaloridine. Toxicol. Appl. Pharmacol. 1977; 42: 285–300
   PubMed Web of Science ®Google Scholar
• Stripp B., Hamrick M. E., Zampagione N. G., Gillette J. R. The effect of spironolactone on drug metabolism by hepatic microsomes. J. Pharmacol. Exp. Ther. 1971; 176: 766–771
   PubMed Web of Science ®Google Scholar
• Hamrick M. E., Zampaglione N., Stripp B., Gillette J. R. Investigation of the effects of methyltestosterone, cortisone and spironolactone on the hepatic microsomal mixed function oxidase system in male and female rats. Biochem. Pharmacol 1973; 22: 293–310
   PubMed Web of Science ®Google Scholar
• Menard R. H., Stripp B., Gillette J. R. Spironolactone and testicular cytochrome P-450: Decreased testosterone formation in several species and changes in hepatic drug metabolism. Endocrinology 1974; 94: 1628–1636
   PubMed Web of Science ®Google Scholar
• Menard R. H., Martin H. F., Stripp B., Gillette J. R., Bartter F. C. Spironolactone and cytochrome P-450: Impairment of steroid hydroxylation in the adrenal cortex. Life Sci. 1974; 15: 1639–1648
   PubMed Web of Science ®Google Scholar
• Stripp B., Taylor A. A., Bartter F. C., Gillette J. R., Loriaux D. L., Easley R., Menard R. H. Effect of spironolactone on sex hormones in man. J. Clin. Endocrinol. Metab. 1975; 41: 777–781
   PubMed Web of Science ®Google Scholar
• Menard R. H., Bartter F. C., Gillette J. R. Spironolactone and cytochrome P-450: Impairment of steroid 21-hydroxylation in the adrenal cortex. Arch. Biochem. Biophys. 1976; 173: 395–402
   PubMed Web of Science ®Google Scholar
• Menard R. H., Guenthner T. M., Kon H., Gillette J. R. Studies on the destruction of adrenal and testicular cytochrome P450 by spironolactone. J. Biol. Chem. 1979; 254: 1726–1733
   PubMed Web of Science ®Google Scholar
• Thorgeirsson S. S., Jollow D. J., Sasame H. A., Green I., Mitchell J. R. The role of cytochrome P-450 in N-hydroxylation of 2-acetylaminofluorene. Mol. Pharmacol. 1973; 9: 398–404
   PubMed Web of Science ®Google Scholar
• Mulder G. J., Hinson J. A., Nelson W. L., Thorgeirsson S. S. Role of sulfotransferase from rat liver in the mutagenicity of N-hydroxy-2-acetylaminofluorene in Salmonella typhimurium. Biochem. Pharmacol 1977; 26: 1356–1358
   Web of Science ®Google Scholar
• Andrews L. S., Hinson J. A., Gillette J. R. Studies on the mutagenicity of N-hydroxy-2-acetylaminofluorene in the Ames-Salmonella mutagenesis test system. Biochem. Pharmacol. 1978; 27: 2399–2408
   PubMed Web of Science ®Google Scholar
• Andrews L. S., Fysh J. M., Hinson J. A., Gillette J. R. Ascorbic acid inhibits covalent binding of enzymatically generated 2-acetylaminofluorene-Af-sulfate to DNA under conditions in which it increases mutagenesis in Salmonella TA1538. Life Sci. 1979; 24: 59–64
   PubMed Web of Science ®Google Scholar
• Andrews L. A., Pohl L. R., Hinson J. A., Fisk C. L., Gillette J. R. Production of a dimer of 2-acetylaminofluorene during the sulfation of N-hydroxy-2-acetylaminofluorene in vitro. Drug Metab. Dispos 1979; 7: 296–300
   PubMed Web of Science ®Google Scholar
• Nelson S. D., Mitchell J. R., Dybing E., Sasame H. A. Cytochrome P-450-mediated oxidation of 2-hydroxyestrogens to reactive intermediates. Biochem. Biophys. Res. Comtnun. 1976; 70: 1157–1165
   PubMed Web of Science ®Google Scholar
• Reid W. D. Mechanism of allyl alcohol-induced hepatic necrosis. Experientia 1972; 28: 1058–1061
   PubMedGoogle Scholar
• Thorgeirsson S. S., Mitchell J. R., Sasame H. A., Potter W. Z. Biochemical changes after hepatic injury by allyl alcohol and AMvydroxy-2-acetylaminofluorene. Chem.-Biol. Interact. 1976; 15: 139–147
   PubMed Web of Science ®Google Scholar
• Feller D. R., Morita M., Gillette J. R. Reduction of heterocyclic nitro compounds in rat liver (35594). Proc. Soc. Exp. Biol. Med. 1971; 137: 433–437
   Web of Science ®Google Scholar
• Morita M., Feller D. R., Gillette J. R. Reduction of niridazole by rat liver xanthine oxidase. Biochem. Pharmacol. 1971; 20: 217–226
   PubMed Web of Science ®Google Scholar
• Feller D. R., Morita M., Gillette J. R. Enzymatic reduction of niridazole by rat liver microsomes. Biochem. Pharmacol. 1971; 20: 203–215
   PubMed Web of Science ®Google Scholar
• Boyd M. R., Stiko A. W., Sasame H. A. Metabolic activation of nitrofurantoin—Possible implications for carcinogenesis. Biochem. Pharmacol 1979; 28: 601–606
   PubMed Web of Science ®Google Scholar
• Sasame H. A., Boyd M. R. Superoxide and hydrogen peroxide production and NADPH oxidation stimulated by nitrofurantoin in lung microsomes: Possible implications for toxicity. Life Sci. 1979; 24: 1091–1096
   PubMed Web of Science ®Google Scholar
• Boyd M. R., Catignani G. L., Sasame H. A., Mitchell J. R., Stiko A. W. Acute pulmonary injury in rats by nitrofurantoin and modification by vitamin E dietary fat, and oxygen. Am. Rev. Respir. Dis. 1979; 120: 93–99
   PubMed Web of Science ®Google Scholar
• Reddy B. G., Pohl L. R., Krishna G. The requirement of the gut flora in nitrobenzene-induced methemoglobinemia in rats. Biochem. Pharmacol. 1976; 25: 1119–1122
   PubMed Web of Science ®Google Scholar
• Maling H. M., Highman B., Williams M. A., Saul W., Butler W. M., Jr., Brodie B. B. Reduction by pretreatment with Dibenamine of hepatotoxicity induced by carbon tetrachloride, thioacetamide or dimethylnitrosamine. Toxicol. Appl. Pharmacol. 1974; 27: 380–394
   PubMed Web of Science ®Google Scholar
• Stripp B., Sipes I. G., Maling H. M., Gillette J. R. Dibenamine impairment of rat hepatic microsomal enzymes and its relation to hepatotoxicity induced by CC14 and dimethylnitrosamine (DMN). Drug Metab. Dispos. 1974; 2: 464–468
   PubMed Web of Science ®Google Scholar
• Maling H. M., Stripp B., Sipes I. G., Highman B., Saul W., Williams M. A. Enhanced hepatotoxicity of carbon tetrachloride, thioacetamide and dimethylnitrosamine by pretreatment of rats with ethanol and some comparisons with potentiation by isopropanol. Toxicol. Appl. Pharmacol 1975; 33: 291–308
   PubMed Web of Science ®Google Scholar
• Rao G. S., Krishna G., Gillette J. R. Enzymatic formation of chemically reactive metabolites of Af-nitrosodesmethyl tripelen-namine by a mechanism other than Af-dealkylation. Biochem. Pharmacol. 1975; 24: 1707–1711
   PubMed Web of Science ®Google Scholar
• Rao G. S., Krishna G. Drug-nitrate interactions: Formation of N-nitroso, C-nitroso and nitro compounds from sodium nitrite and various drugs under physiological conditions. J. Pharm. ScL 1975; 64: 1579–1581
   PubMed Web of Science ®Google Scholar
• Rao G., Krishna G., Gillette J. R. Drug-nitrite interactions: The lack of toxicity of a N-nitroso derivative of tripelennamine formed in the rat. Toxicol. Appl. Pharmacol. 1975; 34: 264–270
   PubMed Web of Science ®Google Scholar
• Rao G., Krishna G., Gillette J. R. Metabolism, tissue distribution and covalent binding of tripelennamine and N-nitroso derivative in the rat. J. Pharmacol. Exp. Ther. 1975; 195: 433–440
   PubMed Web of Science ®Google Scholar
• Davis D. C., Hashimoto M., Gillette J. R. Effects of bromo-benzene and carbon tetrachloride on the synthesis and release of proteins by perfused rat liver. Biochem. Pharmacol. 1973; 22: 1989–2001
   PubMed Web of Science ®Google Scholar
• Castro J. A., DeFerreyra E. C., DeCastro C. R., DeFenos O. M., Sasame H., Gillette J. R. Prevention of carbon tetrachloride-induced necrosis by inhibitors of drug metabolism: Further studies on their mechanism of action. Biochem. Pharmacol. 1974; 23: 295–302
   PubMed Web of Science ®Google Scholar
• Maling H. M., Eichelbaum F. M., Saul W., Sipes I. G., Brown E. A., Gillette J. R. Nature of the protection against carbon tetrachloride-induced hepatotoxicity produced by pretreatment with dibenamine [A^-(2-choroethyl) dibenzylamine]. Biochem. Pharmacol. 1974; 23: 1479–1491
   PubMed Web of Science ®Google Scholar
• Sipes I. G., Krishna G., Gillette J. R. Bioactivation of carbon tetrachloride, chloroform and bromotrichloromethane: Role of cytochrome P-450. Life Sci. 1977; 20: 1541–1548
   PubMed Web of Science ®Google Scholar
• Pohl L. R., Branchflower R. V., Highet R. J., Martin J. L., Nunn D. S., Monks T. J., George J. W., Hinson J. A. The formation of diglutathionyl dithiocarbonate as a metabolite of chloroform, bromotrichloromethane, and carbon tetrachloride. Drug Metabol. Dispos. 1981; 9: 334–339
   PubMed Web of Science ®Google Scholar
• Mico B. A., Branchflower R. V., Pohl L. R., Pudzianowski A. T., Loew G. H. Oxidation of carbon tetrachloride, bromotrichloromethane, and carbon tetrabromide by rat liver microsomes to electrophilic halogens. Life Sci. 1982; 30: 131–137
   PubMed Web of Science ®Google Scholar
• Mico B. A., Pohl L. R. Metabolism of carbon tetrachloride to electrophilic chlorine by liver microsomes: Exclusion of cytochrome P-450 catalyzed chloroperoxidase reaction. Biochem. Biophys. Res. Commun. 1982; 10: 27–31
   Google Scholar
• Mico B. A., Branchflower R. V., Pohl L. R. Formation of electrophilic chlorine from carbon tetrachloride involvement of cytochrome P-450. Biochem. Pharmacol. 1983; 32: 2357–2359
   PubMed Web of Science ®Google Scholar
• Mico B. A., Pohl L. R. Reductive oxygenation of carbon tetrachloride: Trichloromethylperoxyl radical as a possible intermediate in the conversion of carbon tetrachloride to electrophilic chlorine. Arch. Biochem. Biophys. 1983; 225: 596–609
   PubMed Web of Science ®Google Scholar
• Pohl L. R., George J. W. Identification of dichloromethyl carbene as a metabolite of carbon tetrachloride. Biochem. Biophys. Res. Commun. 1983; 117: 367–371
   PubMed Web of Science ®Google Scholar
• Pohl L. R., Schulick R. D., Highet R. J., George J. W. Reductive-oxygenation mechanism of metabolism of carbon tetrachloride to phosgene by cytochrome P-450. Mol. Pharmacol. 1984; 25: 318–321
   PubMed Web of Science ®Google Scholar
• Davies H. W., Britt S., Pohl L. R. Carbon tetrachloride and 2-isopropyl-4-pentenamide-induced inactivation of cytochrome P-450 leads to heme-derived protein adducts. Arch. Biochem. Biophys. 1986; 244: 387–392
   PubMed Web of Science ®Google Scholar
• Ilett K. F., Reid W. D., Sipes I. G., Krishna G. Chloroform toxicity in mice: Correlation of renal and hepatic necrosis with covalent binding of metabolites to tissue macromolecules. Exp. Mol. Pathol 1973; 19: 215–229
   PubMed Web of Science ®Google Scholar
• Docks E. L., Krishna G. The role of glutathione in chloroform-induced hepatotoxicity. Exp. Mol. Pathol. 1976; 24: 13–22
   PubMed Web of Science ®Google Scholar
• Pohl L. R., Bhooshan B., Whittaker N. F., Krishna G. Phosgene: A metabolite of chloroform. Biochem. Biophys. Res. Commun. 1977; 79: 684–691
   PubMed Web of Science ®Google Scholar
• Pohl L. R., Krishna G. Deuterium isotope effect in bioactivation and hepatotoxicity of chloroform. Life Sci. 1978; 23: 1067–1072
   PubMed Web of Science ®Google Scholar
• Pohl L. R., George J. W., Martin J. L., Krishna G. Deuterium isotope effect in in vivo bioactivation of chloroform to phosgene. Biochem. Pharmacol. 1979; 28: 561–563
   PubMed Web of Science ®Google Scholar
• Pohl L. R., Martin J. L., George J. W. Mechanism of metabolic activation of chloroform by rat liver microsomes. Biochem. Pharmacol. 1980; 29: 3271–3276
   PubMed Web of Science ®Google Scholar
• Branchflower R. V., Pohl L. R. Investigation of the mechanism of the potentiation of chloroform-induced hepatotoxicity and nephrotoxicity by methyl n-butyl ketone. Toxicol. Appl. Pharmacol 1981; 61: 407–413
   PubMed Web of Science ®Google Scholar
• Branchflower R. V., Schulick R. D., George J. W., Pohl L. R. Comparison of the effects of methyl-n-butyl ketone and phenobarbital on rat liver cytochrome P-450 and the metabolism of chloroform to phosgene. Toxicol. Appl. Pharmacol. 1983; 71: 414–421
   PubMed Web of Science ®Google Scholar
• Branchflower R. V., Nunn D. S., Highet R. J., Smith J. H., Hook J. B., Pohl L. R. Nephrotoxicity of chloroform: Metabolism to phosgene by the mouse kidney. Toxicol. Appl. Pharmacol. 1984; 72: 159–168
   PubMed Web of Science ®Google Scholar
• Pohl L. R., George J. W., Satoh H. Strain and sex differences in chloroform-induced nephrotoxicity. Different rates of metabolism of chloroform to phosgene by the mouse kidney. Drug Metab. Dispos. 1984; 12: 304–308
   PubMed Web of Science ®Google Scholar
• Krishna G. Covalent binding of drugs to tissue macromolecules as a biochemical mechanism of drug toxicities with special emphasis on chloramphenicol and thiamphenicol. Postgrad. Med. J. 1974; 50: 13–11
   Google Scholar
• Pohl L. R., Krishna G. Study of the mechanism of metabolic activation of chloramphenicol by rat liver microsomes. Biochem. Pharmacol 1978; 27: 335–341
   PubMed Web of Science ®Google Scholar
• Pohl L. R., Nelson S. D., Krishna G. Investigation of the mechanism of the metabolic activation of chloramphenicol by rat liver microsomes: Identification of a new metabolite. Biochem. Pharmacol 1978; 27: 491–496
   PubMed Web of Science ®Google Scholar
• Pohl L. R., Reddy G. B., Krishna G. A new pathway of metabolism of chloramphenicol which influences the interpretation of its irreversible binding to protein in vivo. Biochem. Pharmacol 1979; 28: 2433–2440
   PubMed Web of Science ®Google Scholar
• Martin J. L., George J. W., Pohl L. R. Glutathione-dependent dechlorination of chloramphenicol by cytosol. Drug Metab. Dispos. 1980; 8: 93–97
   PubMed Web of Science ®Google Scholar
• Martin J. L., Gross B. J., Morris P., Pohl L. R. Mechanism of glutathione-dependent dechlorination of chloramphenicol and thiamphenicol by cytosol of rat liver. Drug Metab. Dispos. 1980; 8: 371–375
   PubMed Web of Science ®Google Scholar
• Gross B. J., Branchflower R. V., Burke T. R., Lees D. E., Pohl L. R. Bone marrow toxicity in vitro and chloramphenicol and its metabolites. Toxicol. Appl. Pharmacol. 1982; 64: 557–565
   PubMed Web of Science ®Google Scholar
• Morris P. A., Burke T. R., Jr., George J. W., Pohl L. R. A new pathway for the oxidative metabolism of chloramphenicol by rat liver microsomes. Drug Metab. Dispos. 1982; 10: 439–445
   PubMed Web of Science ®Google Scholar
• Morris P. L., Burke T. E., Jr., Pohl L. R. Reductive dechlorination of chloramphenicol by rat liver microsomes. Drug Metab. Dispos. 1983; 11: 126–130
   PubMed Web of Science ®Google Scholar
• Burke T. R., Jr., Martin J. L., George J. W., Pohl L. R. Investigation of the mechanism of defluorination of enflurane in rat liver microsomes with specifically deuterated derivatives. Biochem. Pharmacol 1980; 29: 1623–1626
   PubMed Web of Science ®Google Scholar
• Burke T. R., Branchflower R. V., Lees D. E., Pohl L. R. Mechanism of defluorination of enflurane: Identification of an organic metabolite in rat and man. Drug Metab. Dispos. 1981; 9: 19–24
   PubMed Web of Science ®Google Scholar
• Davis D. C., Schroeder D. H., Gram T. E., Reagan R. L., Gillette J. R. A comparison of the effect of halothane and CC14 on the hepatic drug metabolizing system. J. Pharmacol. Exp. Ther. 1971; 177: 556–566
   PubMed Web of Science ®Google Scholar
• Sipes I. G., Gandolfi A. J., Pohl L. R., Krishna G., Brown B. R., Jr. Comparison of the biotransformation and hepatotoxicity of halothane and deuterated halothane. J. Pharmacol. Exp. Ther. 1980; 214: 716–720
   PubMed Web of Science ®Google Scholar
• Pohl L. R., Gillette J. R. A perspective on halothane-induced hepatotoxicity. Anesth. Analg. 1982; 61: 809–811
   PubMed Web of Science ®Google Scholar
• Satoh H., Fukuda Y., Anderson D. K., Ferrans V. J., Gillette J. R., Pohl L. R. Immunological studies on the mechanism of halothane-induced hepatotoxicity: Immunohistochemical evidence of trifluoroacetylated hepatocytes. J. Pharmacol. Exp. Ther. 1985; 233: 857–862
   PubMed Web of Science ®Google Scholar
• Satoh H., Gillette J. R., Davies H. W., Schulick R. D., Pohl L. R. Immunochemical evidence of trifluoroacetylated cytochrome P-450 in the liver of halothane-treated rats. Mol. Pharmacol 1985; 28: 468–474
   PubMed Web of Science ®Google Scholar
• Christ D. D., Satoh H., Kenna J. G., Pohl L. R. Potential metabolic basis for enflurane hepatitis and the apparent cross-sen-sitization between enflurane and halothane. Drug Metab. Dispos. 1988; 16: 135–140
   PubMed Web of Science ®Google Scholar
• Kenna J. G., Satoh H., Christ D. D., Pohl L. R. Metabolic basis for a drug hypersensitivity: Antibodies in sera from patients with halothane hepatitis recognize liver neoantigens that contain the trifluoroacetyl group derived from halothane. J. Pharmacol. Exp. Ther. 1988; 245: 1103–1109
   PubMed Web of Science ®Google Scholar
• Long R. M., Satoh H., Martin B. M., Kimura S., Gonzalez F. J., Pohl L. R. Rat liver carboxylesterase: cDNA cloning, sequencing, and evidence for a multigene family. Biochem. Biophys. Res. Commun. 1988; 156: 866–873
   PubMed Web of Science ®Google Scholar
• Christ D. D., Kenna J. G., Krammerer W., Satoh H., Pohl L. R. Enflurane metabolism produces covalently bound liver adducts recognized by antibodies from patients with halothane hepatitis. Anesthesiology 1988; 69: 833–838
   PubMed Web of Science ®Google Scholar
• Satoh H., Martin B. M., Schulick A. H., Christ D. D., Kenna J. G., Pohl L. R. Human anti-endoplasmic reticulum antibodies in sera of patients with halothane-induced hepatitis are directed against a trifluoroacetylated carboxylesterase. Proc. Natl. Acad. Sci. USA 1989; 86: 322–326
   PubMed Web of Science ®Google Scholar
• Martin J. L., Kenna J. G., Pohl L. R. Antibody assays for the detection of patients sensitized to halothane. Anesth. Analg. 1990; 70: 154–159
   PubMed Web of Science ®Google Scholar
• Kenna J. G., Martin J. L., Satoh H., Pohl L. R. Factors affecting the expression of trifluoroacetylated liver microsomal protein neoantigens in rats treated with halothane. Drug Metab. Dispos. 1990; 18: 788–793
   PubMed Web of Science ®Google Scholar
• Martin J. L., Pumford N. R., LaRosa A. C., Martin B. M., Gonzaga H. M. S., Beaven M. A., Pohl L. R. A metabolite of halothane covalently binds to an endoplasmic reticulum protein that is highly homologous to phosphatidylinositol-specific phospholipase c-α but has no activity. Biochem. Biophys. Res. Commun. 1991; 178: 679–685
   PubMed Web of Science ®Google Scholar
• Hayden P. J., Ichimura T., McCann D. J., Pohl L. R., Stevens J. L. Detection of cysteine conjugate metabolite adduct formation with specific mitochondrial proteins using antibodies raised against halothane metabolite adducts. J. Biol. Chem. 1991; 66: 18415–18418
   Google Scholar
• Martin J. L., Dubbink D. A., Plevak D. J., Peronne A., Taswell H. F., Hay E. J., Pumford N. R., Pohl L. R. Halothane hepatitis 28 years after primary exposure. Anesth. Analg. 1992; 74: 605–608
   PubMed Web of Science ®Google Scholar
• Butler L. E., Thomassen D., Martin J. L., Martin B. M., Kenna J. G., Pohl L. R. The calcium-binding protein calreticulum is covalently modified in rat liver by a reactive metabolite of the inhalation anesthetic halothane. Chem. Res. Toxicol 1992; 5: 406–412
   PubMed Web of Science ®Google Scholar
• Kenna J. G., Martin J. L., Pohl L. R. The topography of trifluoroacetylated protein antigens in liver microsomal fractions from halothane treated rats. Biochem. Pharmacol 1992; 44: 621–629
   PubMed Web of Science ®Google Scholar
• Harris J. W., Jones J. P., Martin J. L., LaRosa A. C., Olson M. J., Pohl L. R., Anders M. W. Pentahaloethane-based chlorofluorocarbon substitutes and halothane: Correlation of in vivo hepatic protein trifluoroacetylation and urinary trifluoroacetic acid excretion with calculated enthalpies of activation. Chem. Res. Toxicol 1992; 5: 720–725
   PubMed Web of Science ®Google Scholar
• Pumford N. R., Martin B. M., Thomassen D., Burris J. A., Kenna J. G., Martin J. L., Pohl L. R. Serum antibodies from halothane hepatitis patients react with the rat endoplasmic reticulum protein ERp72. Chem. Res. Toxicol 1993; 6: 609–615
   PubMed Web of Science ®Google Scholar
• Reynolds E. S. Liver parenchymal cell injury. IV. Pattern of incorporation of carbon and chlorine from carbon tetrachloride into chemical constituents of liver in vivo. J. Pharmacol, Exp. Ther 1967; 155: 117–126
   PubMed Web of Science ®Google Scholar
• Boyd M. R., Burka L. T., Wilson B. J. Distribution, excretion, and binding of radioactivity in the rat after intraperitoneal administration of the lung-toxic furan, [14C]4-ipomeanol. Toxicol. Appl. Pharmacol 1975; 32: 147–157
   PubMed Web of Science ®Google Scholar
• Gillette J. R. A perspective on the role of chemically reactive metabolites of foreign compounds in toxicity. I. Correlation of changes in covalent binding of reactivity metabolites with changes in the incidence and severity of toxicity. Biochem. Pharmacol 1974; 23: 2785–2794
   PubMed Web of Science ®Google Scholar
• Boelsterli U. A. Specific targets of covalent drug-protein interactions in hepatocytes and their toxicological significance in drug-induced liver injury. Drug Metab. Rev. 1993; 25: 395–451
   PubMed Web of Science ®Google Scholar
• Gillette J. R. A perspective on the role of chemically reactive metabolites of foreign compounds in toxicity. II. Alterations in the kinetics of covalent binding. Biochem. Pharmacol 1974; 23: 2927–2938
   PubMed Web of Science ®Google Scholar
• Gillette J. R. Formation of reactive metabolites as a cause of drug toxicity, in Ciba Foundation Symposium 26. The Poisoned Patient. The Role of the Laboratory. Associated Scientific Publishers, Amsterdam 1974; 29–55
   Google Scholar
• Gillette J. R. The problem of chemically reactive metabolites. Drug Metab. Rev. 1982; 13: 941–961
   PubMed Web of Science ®Google Scholar
• Gillette J. R. The use of theoretical pharmacokinetic concepts in studies of the mechanisms of formation of chemically reactive metabolites in vitro and in vivo. Drug Metabol. Rev. 1983; 14: 9–33
   PubMed Web of Science ®Google Scholar
• Gillette J. R. Significance of covalent binding of chemically reactive metabolites of foreign compounds to proteins and lipids. Biological Reactive Intermediates 111, J. J. Kocsis, D. J. Jollow, C. M. Witmer, J. O. Nelson, R. Snyder. Plenum. 1986; 63–82
   Google Scholar
• Walsh C., Cromantie T., Marcotte P., Spencer R. Suicide substrates for flavoprotein enzymes. Methods Enzymol. 1978; 53: 437–448
   PubMedGoogle Scholar
• Gillette J. R. Kinetics of decomposition of chemically unstable metabolites in the presence of nucleophiles: Derivation of equations used in graphical analyses. Pharmacology 1980; 20: 64–86
   PubMed Web of Science ®Google Scholar
• Sasame H. A., Liberato D. J., Gillette J. R. The formation of a glutathione conjugate derived from propranolol. Drug Metab. Dispos. 1987; 15: 349–355
   PubMed Web of Science ®Google Scholar
• Monks T. J., Lau S. S., Gillette J. R. Diffusion of reactive metabolites out of hepatocytes: Studies with bromobenzene. J. Pharmacol. Exp. Ther. 1984; 228: 393–399
   PubMed Web of Science ®Google Scholar
• Gillette J. R., Lau S. S., Monks T. J. Intra- and extracellular formation of metabolites from chemically reactive species. Biochem. Soc. Trans. 1984; 12: 4–7
   PubMed Web of Science ®Google Scholar
• Lau S. S., Monks T. J., Greene K. E., Gillette J. R. Detection and half-life of bromobenzene-3,4-oxide in blood. Xeno-biotica 1984; 14: 539–543
   PubMed Web of Science ®Google Scholar
• Pang K. S., Rowland M. Hepatic clearance of drugs. II. Experimental evidence for acceptance of the “well-stirred” model over the “parallel tube” model using lidocaine in the perfused rat liver in situ preparation. J. Pharmacokinet. Biopharm. 1977; 5: 655–680
   PubMedGoogle Scholar
• Pang K. S., Gillette J. R. Kinetics of metabolite formation and elimination in the perfused rat liver preparation: Differences between the elimination of preformed acetaminophen and acetaminophen formed from phenacetin. J. Pharmacol. Exp. Ther. 1978; 207: 178–194
   PubMed Web of Science ®Google Scholar
• Nagata K., Liberto D. J., Gillette J. R., Sasame H. A. An unusual metabolite of testosterone. 17-hydroxy-4,6-androstadiene-3-one. Drug Metab. Dispos. 1986; 14: 559–565
   PubMed Web of Science ®Google Scholar
• Korzekwa K. R., Trager W. F., Nagata K., Parkinson A., Gillette J. R. Isotope effect studies on the mechanism of the cytochrome P-450IIA1-catalyzed formation of A6-testosterone from testosterone. Drug Metab. Dispos. 1990; 18: 974–979
   PubMed Web of Science ®Google Scholar
• Korzekwa K. R., Trager W. F., Gillette J. R. Theory for the observed isotope effects from enzymatic systems that form multiple products via branched reaction pathways: Cytochrome P-450. Biochemistry 1989; 28: 9012–9018
   PubMed Web of Science ®Google Scholar
• Harada N., Miwa G. T., Walsh J. R., Lu A. Y. H. Kinetic isotope effects on cytochrome P-450-catalyzed oxidation reactions. Evidence for the irreversible formation of an active oxygen intermediate of cytochrome P-448. J. Biol. Chem. 1984; 259: 3005–3010
   PubMed Web of Science ®Google Scholar
• Gillette J. R., Darbyshire J. F., Sugiyama K. Theory for the observed isotope effects on the formation of multiple products by different kinetic mechanisms of cytochrome P450 enzymes. Biochemistry 1994; 33: 2927–2937
   PubMed Web of Science ®Google Scholar
• Darbyshire J. F., Gillette J. R., Nagata K., Sugiyama K. Deuterium isotope effects on A-ring and D-ring metabolism of testosterone by CYP2C11: Evidence for dissociation of activated enzyme-substrate complexes. Biochemistry 1994; 33: 2938–2944
   PubMed Web of Science ®Google Scholar